Literature DB >> 19269661

Impairment in reactivation of a latency associated transcript (LAT)-deficient HSV-2 is not solely dependent on the latent viral load or the number of CD8(+) T cells infiltrating the ganglia.

Yo Hoshino1, Lesley Pesnicak, Stephen E Straus, Jeffrey I Cohen.   

Abstract

The HSV latency-associated transcript (LAT) is abundantly expressed during virus latency. Previous studies have shown that the latent viral load and CD8(+) T cells in ganglia influence the rate of reactivation of HSV. While LAT is important for efficient reactivation and establishment of latency, it is uncertain how LAT affects either the HSV latent viral load or CD8(+) T cell infiltration of ganglia. We infected mice with LAT-deficient or LAT-restored HSV-2 at a wide range of inocula. We found that the reduced rate of spontaneous ex-vivo reactivation of the LAT-deficient virus was not associated with a higher number of CD8(+) T cells in the ganglia. Reactivation rates were lower for LAT-deficient than LAT restored HSV-2 even when the latent viral loads were similar, indicating that differences in reactivation were not solely dependent on the latent viral load. Therefore, LAT likely has additional functions important for reactivation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269661      PMCID: PMC2782611          DOI: 10.1016/j.virol.2009.02.004

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  46 in total

1.  Virus-induced neuronal apoptosis blocked by the herpes simplex virus latency-associated transcript.

Authors:  G C Perng; C Jones; J Ciacci-Zanella; M Stone; G Henderson; A Yukht; S M Slanina; F M Hofman; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  Science       Date:  2000-02-25       Impact factor: 47.728

2.  Regions of the herpes simplex virus type 1 latency-associated transcript that protect cells from apoptosis in vitro and protect neuronal cells in vivo.

Authors:  Maryam Ahmed; Martin Lock; Cathie G Miller; Nigel W Fraser
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

3.  Prophylactic and therapeutic effects of human immunoglobulin on the pathobiology of HSV-1 infection, latency, and reactivation in mice.

Authors:  Sarat K Dalai; Lesley Pesnicak; Georgina F Miller; Stephen E Straus
Journal:  J Neurovirol       Date:  2002-02       Impact factor: 2.643

4.  Early intervention with high-dose acyclovir treatment during primary herpes simplex virus infection reduces latency and subsequent reactivation in the nervous system in vivo.

Authors:  N M Sawtell; R L Thompson; L R Stanberry; D I Bernstein
Journal:  J Infect Dis       Date:  2001-09-10       Impact factor: 5.226

5.  The latency-associated transcript gene enhances establishment of herpes simplex virus type 1 latency in rabbits.

Authors:  G C Perng; S M Slanina; A Yukht; H Ghiasi; A B Nesburn; S L Wechsler
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Herpes simplex virus type 1 latency-associated transcript gene promotes neuronal survival.

Authors:  R L Thompson; N M Sawtell
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  The 2.2-kilobase latency-associated transcript of herpes simplex virus type 2 does not modulate viral replication, reactivation, or establishment of latency in transgenic mice.

Authors:  K Wang; L Pesnicak; E Guancial; P R Krause; S E Straus
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

8.  Persistent elevated expression of cytokine transcripts in ganglia latently infected with herpes simplex virus in the absence of ganglionic replication or reactivation.

Authors:  S H Chen; D A Garber; P A Schaffer; D M Knipe; D M Coen
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

9.  Biological properties of herpes simplex virus 2 replication-defective mutant strains in a murine nasal infection model.

Authors:  C A Jones; T J Taylor; D M Knipe
Journal:  Virology       Date:  2000-12-05       Impact factor: 3.616

10.  Gamma interferon can prevent herpes simplex virus type 1 reactivation from latency in sensory neurons.

Authors:  T Liu; K M Khanna; B N Carriere; R L Hendricks
Journal:  J Virol       Date:  2001-11       Impact factor: 5.103

View more
  6 in total

1.  Herpes simplex virus 1 microRNAs expressed abundantly during latent infection are not essential for latency in mouse trigeminal ganglia.

Authors:  Martha F Kramer; Igor Jurak; Jean M Pesola; Sandrine Boissel; David M Knipe; Donald M Coen
Journal:  Virology       Date:  2011-07-23       Impact factor: 3.616

2.  Influence of herpes simplex virus 1 latency-associated transcripts on the establishment and maintenance of latency in the ROSA26R reporter mouse model.

Authors:  M P Nicoll; J T Proença; V Connor; S Efstathiou
Journal:  J Virol       Date:  2012-06-13       Impact factor: 5.103

Review 3.  The molecular basis of herpes simplex virus latency.

Authors:  Michael P Nicoll; João T Proença; Stacey Efstathiou
Journal:  FEMS Microbiol Rev       Date:  2012-01-10       Impact factor: 16.408

4.  Nasal Immunization Confers High Avidity Neutralizing Antibody Response and Immunity to Primary and Recurrent Genital Herpes in Guinea Pigs.

Authors:  Josefine Persson; Yuan Zhang; Thorunn A Olafsdottir; Karolina Thörn; Tina M Cairns; Frank Wegmann; Quentin J Sattentau; Roselyn J Eisenberg; Gary H Cohen; Ali M Harandi
Journal:  Front Immunol       Date:  2016-12-26       Impact factor: 7.561

5.  Gene editing and elimination of latent herpes simplex virus in vivo.

Authors:  Martine Aubert; Daniel E Strongin; Pavitra Roychoudhury; Michelle A Loprieno; Anoria K Haick; Lindsay M Klouser; Laurence Stensland; Meei-Li Huang; Negar Makhsous; Alexander Tait; Harshana S De Silva Feelixge; Roman Galetto; Philippe Duchateau; Alexander L Greninger; Daniel Stone; Keith R Jerome
Journal:  Nat Commun       Date:  2020-08-18       Impact factor: 17.694

Review 6.  [Mechanisms of herpes simplex virus latency and reactivation].

Authors:  Boqiang Sun; Qiongyan Wang; Dongli Pan
Journal:  Zhejiang Da Xue Xue Bao Yi Xue Ban       Date:  2019-05-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.